Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
CUE
Cue Biopharma, Inc.
Immuno-STAT represents a drug delivery platform for targeted, injectable biologics.
|
$47.73M |
$0.61
-1.43%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$47.07M |
$6.73
+7.00%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$46.58M |
$1.10
+4.76%
|
|
IBIO
iBio, Inc.
The company markets and utilizes an Antibody Discovery Platform (epitope-steering AI, StableHu, EngageTx, ShieldTx) to identify and optimize antibody candidates.
|
$46.32M |
$2.06
-2.61%
|
|
HOWL
Werewolf Therapeutics, Inc.
Werewolf Therapeutics develops conditionally activated immunotherapies for cancer, aligning with Biotech - Oncology.
|
$45.90M |
$0.94
+2.62%
|
|
COSG
Cosmos Group Holdings Inc.
Cana Laboratories' facility upgrades and a 5-year Pharmex contract manufacturing agreement indicate COSG's direct contract manufacturing service in pharma.
|
$45.86M |
$0.00
|
|
LVTX
LAVA Therapeutics N.V.
LAVA Therapeutics operates in oncology biotech, developing cancer therapies based on its Gammabody platform.
|
$45.77M |
$1.65
-5.17%
|
|
RLYB
Rallybio Corporation
Core focus on rare diseases with lead and preclinical assets addressing complement dysregulation and iron overload.
|
$43.41M |
$8.20
-1.62%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$42.15M |
$2.98
+9.37%
|
|
IXHL
Incannex Healthcare Limited
Incannex develops oral small-molecule therapeutics as fixed-dose drug combinations (IHL-42X).
|
$42.12M |
$3.63
+0.69%
|
|
CVM
CEL-SCI Corporation
Direct product category for CEL-SCI's lead immunotherapy for cancer (Multikine) under oncology biotech.
|
$41.62M |
$4.91
+5.82%
|
|
ALGS
Aligos Therapeutics, Inc.
Aligos develops oral small-molecule therapeutics across its pipeline (HBV CAM-E, THR-β agonist, and pan-coronavirus protease inhibitor).
|
$41.11M |
$6.75
-11.88%
|
|
NMTC
NeuroOne Medical Technologies Corporation
sEEG-based drug delivery system platform enabling localized therapeutic delivery from neural implants.
|
$40.67M |
$4.83
+5.58%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Actinium directly develops radiopharmaceutical therapies using alpha-emitting isotopes (Ac-225) for oncology (ATNM-400, Actimab-A, Iomab-ACT).
|
$40.55M |
$1.31
+4.80%
|
|
FGEN
FibroGen, Inc.
FibroGen's FG-3246 is an oncology-focused therapeutic program, making Biotech - Oncology a core investment theme.
|
$39.28M |
$9.53
+5.60%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$39.23M |
$4.41
-1.67%
|
|
VERU
Veru Inc.
Veru's lead asset enobosarm is an oral small molecule therapeutic.
|
$39.16M |
$2.43
-1.62%
|
|
INMB
INmune Bio, Inc.
Directly represents INmune Bio's Alzheimer's disease therapeutics focus under the XPro DN-TNF program.
|
$38.55M |
$1.45
+8.21%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Sensei's lead asset targets oncology/cancer indications, fitting the Biotech - Oncology category.
|
$38.46M |
$30.75
+5.24%
|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$38.00M |
$5.32
+1.53%
|
|
ETST
Earth Science Tech, Inc.
ETST's core pharmaceutical operations include compounding pharmacies (RxCompound, Mister Meds) providing outsourced drug manufacturing services.
|
$37.66M |
$0.15
|
|
PASG
Passage Bio, Inc.
PBFT02 is Passage Bio's lead gene therapy program directly developed by the company.
|
$37.10M |
$12.02
+2.91%
|
|
CRVO
CervoMed Inc.
Neflamapimod is an orally administered, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$36.83M |
$4.00
+0.25%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$35.97M |
$5.36
+0.37%
|
|
OKUR
OnKure Therapeutics, Inc.
OKUR operates as a clinical-stage biotech focused on oncology therapies, including mutant-selective PI3Kα inhibitors, directly aligning with Biotech - Oncology.
|
$35.45M |
$2.61
-0.38%
|
|
BOLD
Boundless Bio, Inc.
The company is a biotechnology firm focused on oncology, developing ecDNA-directed cancer therapies, which places it in Biotech - Oncology.
|
$35.37M |
$1.57
-3.37%
|
|
MURA
Mural Oncology plc
Company develops oncology-focused immunotherapies, including engineered cytokine therapies (nemvaleukin) and related assets.
|
$35.34M |
$2.03
-0.49%
|
|
PSTV
Plus Therapeutics, Inc.
Core product: radiopharmaceutical therapy using Rhenium-186 nanoliposomes for CNS cancers.
|
$35.13M |
$6.36
+6.89%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$34.94M |
$6.87
-16.52%
|
|
RDGL
Vivos Inc.
RDGL's core offering is radiopharmaceutical therapy using Y-90 for targeted cancer treatment.
|
$33.31M |
$0.07
|
|
XLO
Xilio Therapeutics, Inc.
Xilio is a clinical-stage biotechnology company focused on oncology therapies, placing it in Biotech - Oncology.
|
$32.14M |
$8.58
+2.75%
|
Showing page 19 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
